NCI-H446 [H446] (ATCC® HTB-171)

Organism: Homo sapiens, human  /  Tissue: lung; derived from metastatic site: pleural effusion  /  Disease: carcinoma; small cell lung cancer

Permits and Restrictions

View Restrictions

Organism Homo sapiens, human
Tissue lung; derived from metastatic site: pleural effusion
Product Format frozen
Morphology epithelial
Culture Properties mixed, adherent and suspension
Biosafety Level 1
Disease carcinoma; small cell lung cancer
Age 61 years
Gender male
Ethnicity Caucasian
Storage Conditions liquid nitrogen vapor phase
Karyotype This is a hypertriploid human cell line. The modal chromosome number is 74, occurring at 22% with polyploidy at 2.5%. Over 25 markers were common to most cells including inv(1)(p32q21), der(1)t(1:4)(q42;q11), i(5q), t(2p13q) and der(19)t(7;HSR;19) (q11;HSR;p13.3). Structurally normal N1 and N13 were absent and normal N4, N5 and N10 were mostly single copies per cell. There were two X/Y pairs per cell.
Derivation
The NCI-H446 cell line was derived by D. Carney, A.F. Gazdar and associates in 1982 from the pleural fluid of a patient with small cell cancer of the lung.
Clinical Data
61 years
Caucasian
male
Tumorigenic Yes
Effects
Yes, in nude mice
Comments

The morphology of the original tumor was not characteristic of SCLC. 

The line is a biochemical and morphological variant of SCLC that expresses neuron specific enolase and the brain isoenzyme of creatine kinase. 

It does not have detectable levels of L-DOPA decarboxylase, bombesin, vasopressin, oxytocin or gastrin releasing peptide. 

C-myc DNA sequences are amplified about 20 fold, and there is a 15 fold increase in c-myc RNA relative to normal cells. 

The line was originally propagated in serum free RPMI 1640 medium supplemented with 10 nM hydrocortisone, 0.005 mg/mL insulin, 0.01 mg/mL transferrin, 10 nM 17-beta-estradiol, and 30 nM sodium selenite.

The cells form transplantable tumors with non-typical SCLC histology.

Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
This is a cell line that grows as both attached and suspended cells. The suspended cells are viable and can be used for subculture.To subculture the attached cells, remove the old medium (recover the suspended cells by centrifugation if desired), rinse the monolayer with fresh 0.25% trypsin, 0.53 mM EDTA and let the culture sit at 37°C until the cells detach. Add fresh medium, disperse cells and transfer to a new flask.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:9 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation
Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
STR Profile
Amelogenin: X,Y
CSF1PO: 13,14
D13S317: 8
D16S539: 12
D5S818: 11
D7S820: 10,11
THO1: 8,9.3
TPOX: 9,11
vWA: 18,19
Isoenzymes
AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 2
Me-2, 0
PGM1, 1-2
PGM3, 1
Name of Depositor AF Gazdar, JD Minna
Year of Origin 1982
References

Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258

Verbeeck MA, et al. Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines. Pathobiology 60: 136-142, 1992. PubMed: 1320893

Basic Documentation
Restrictions

The line is available with the following restrictions:

  1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied.
  2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.

References

Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258

Verbeeck MA, et al. Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines. Pathobiology 60: 136-142, 1992. PubMed: 1320893